Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes

Cancer

Volumn 119, Issue 21, 2013, Pages 3870-3878

  Zeidan, Amer M ^a   Gore, Steven D ^a   McNally, Diane L ^b   Baer, Maria R ^c   Hendrick, Franklin ^b   Mahmoud, Dalia ^d   Davidoff, Amy J ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d CELGENE CORPORATION   (United States)

^e AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

5q deletion; lenalidomide; Medicare population; myelodysplastic syndromes

Indexed keywords

DNA METHYLTRANSFERASE INHIBITOR; LENALIDOMIDE; RECOMBINANT ERYTHROPOIETIN;

AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CHROMOSOME 5Q; CHROMOSOME DELETION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; ICD-9-CM; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

5Q DELETION; LENALIDOMIDE; MEDICARE POPULATION; MYELODYSPLASTIC SYNDROMES;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BLOOD TRANSFUSION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; COHORT STUDIES; FEMALE; HUMANS; MALE; MEDICARE; MYELODYSPLASTIC SYNDROMES; PHYSICIAN'S PRACTICE PATTERNS; THALIDOMIDE; TREATMENT OUTCOME; UNITED STATES;

EID: 84886095194     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28298     Document Type: Article

References (17)

1. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355: 1456-1465.
2. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011; 118: 3765-3776.
3. Ades L, Boehrer S, Prebet T, et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood. 2009; 113: 3947-3952.
4. Ades L, Fenaux P,. Immunomodulating drugs in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2011; 2011: 556-560.
5. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008; 111: 86-93.
6. Greenberg PL, Attar E, Bennett JM, et al. Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 2011; 9: 30-56.
7. Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of 6 cross-sectional physician surveys. J Natl Cancer Inst. 2008; 100: 1542-1551.
8. Sekeres MA,. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. J Natl Compr Canc Netw. 2011; 9: 57-63.
9. RTI International. RTI Spatial Impact Factor Data. rtispatialdata.rti. org/Home/tabid/37/Default.aspx. Accessed September 5, 2011.
10. Davidoff AJ, Hurria A, Zuckerman IH, et al. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol. 2013; 4: 157-165.
11. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96: 3671-3674.
12. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352: 549-557.
13. Davidoff AJ, Weiss SR, Baer MR, et al. Patterns of erythropoiesis- stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. Leuk Res. 2013; 37: 675-680.
14. Wang R, Gross CP, Maggiore RJ, et al. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Leuk Res. 2011l; 35: 904-908.
15. Goldman DP, Joyce GF, Lawless G, et al. Benefit design and specialty drug use. Health Aff (Millwood). 2006; 25: 1319-1331.
16. Goldman DP, Jena AB, Lakdawalla DN, et al. The value of specialty oncology drugs. Health Serv Res. 2010; 45: 115-132.
17. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Version 4.2006. Myelodysplastic Syndromes. Fort Washington, PA: National Comprehensive Cancer Network; 2006.